{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:20:04Z","timestamp":1790961604703,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Navamindradhiraj University Research Fund and the Faculty of Medicine Vajira Hospital, Navamindradhiraj University"},{"name":"the Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-26752-0","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:24:17Z","timestamp":1764325457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Association of noninvasive tests of liver fibrosis with chronic kidney disease in MASLD: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Supatsri","family":"Sethasine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thananda","family":"Trakarnvanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witchakorn","family":"Ruamtawee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nutachat","family":"Treerasoradaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paweena","family":"Susantitaphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"26752_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2025.110860","volume":"145","author":"S Sethasine","year":"2025","unstructured":"Sethasine, S., Suthasmalee, S., Tangjitgamol, S. & Phaloprakarn, C. Contraception and nonalcoholic fatty liver disease in women with prior gestational diabetes mellitus. Contraception 145, 110860. https:\/\/doi.org\/10.1016\/j.contraception.2025.110860 (2025).","journal-title":"Contraception"},{"issue":"3","key":"26752_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. Non-alcoholic fatty liver disease: a global public health perspective. J Hepatol. 70(3), 531\u2013544. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.033 (2019).","journal-title":"J Hepatol."},{"issue":"1","key":"26752_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13006-024-00684-3","volume":"19","author":"S Sethasine","year":"2024","unstructured":"Sethasine, S. & Phaloprakarn, C. Relationship between breastfeeding and hepatic steatosis in women with previous gestational diabetes mellitus. Int Breastfeed J. 19(1), 75. https:\/\/doi.org\/10.1186\/s13006-024-00684-3 (2024).","journal-title":"Int Breastfeed J."},{"issue":"5","key":"26752_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-097114","volume":"15","author":"C Phaloprakarn","year":"2025","unstructured":"Phaloprakarn, C. & Sethasine, S. Association between glucose intolerance and fatty liver disease in women with previous gestational diabetes mellitus in urban Thailand: A prospective cohort study. BMJ Open 15(5), e097114. https:\/\/doi.org\/10.1136\/bmjopen-2024-097114 (2025).","journal-title":"BMJ Open"},{"issue":"9","key":"26752_CR5","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","volume":"119","author":"C Grander","year":"2023","unstructured":"Grander, C., Grabherr, F. & Tilg, H. Non-alcoholic fatty liver disease: Pathophysiological concepts and treatment options. Cardiovasc Res. 119(9), 1787\u20131798. https:\/\/doi.org\/10.1093\/cvr\/cvad095 (2023).","journal-title":"Cardiovasc Res."},{"issue":"7","key":"26752_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher, G., Tilg, H. & Byrne, C. D. Non-alcoholic fatty liver disease: A multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 6(7), 578\u2013588. https:\/\/doi.org\/10.1016\/S2468-1253(21)00020-0 (2021).","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"26752_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2023.2209686","author":"S Sethasine","year":"2023","unstructured":"Sethasine, S., Simasingha, N., Ratana-Amornpin, S. & Mahachai, V. Real world for management of hepatocellular carcinoma: A large population-based study. Scand J Gastroenterol https:\/\/doi.org\/10.1080\/00365521.2023.2209686 (2023).","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"26752_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. Hepatology 67(1), 328\u2013357. https:\/\/doi.org\/10.1002\/hep.29367 (2018).","journal-title":"Hepatology"},{"issue":"1","key":"26752_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101506","volume":"50","author":"J Bilson","year":"2024","unstructured":"Bilson, J., Mantovani, A., Byrne, C. D. & Targher, G. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes Metab. 50(1), 101506. https:\/\/doi.org\/10.1016\/j.diabet.2023.101506 (2024).","journal-title":"Diabetes Metab."},{"issue":"4","key":"26752_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41581-021-00519-y","volume":"18","author":"TY Wang","year":"2022","unstructured":"Wang, T. Y. et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol. 18(4), 259\u2013268. https:\/\/doi.org\/10.1038\/s41581-021-00519-y (2022).","journal-title":"Nat Rev Nephrol."},{"issue":"4","key":"26752_CR11","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1080\/13813455.2020.1745851","volume":"128","author":"N Sharma","year":"2022","unstructured":"Sharma, N., Sircar, A., Anders, H. J. & Gaikwad, A. B. Crosstalk between kidney and liver in non-alcoholic fatty liver disease: Mechanisms and therapeutic approaches. Arch Physiol Biochem. 128(4), 1024\u20131038. https:\/\/doi.org\/10.1080\/13813455.2020.1745851 (2022).","journal-title":"Arch Physiol Biochem."},{"key":"26752_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154433","volume":"115","author":"DQ Sun","year":"2021","unstructured":"Sun, D. Q. et al. MAFLD and risk of CKD. Metabolism 115, 154433. https:\/\/doi.org\/10.1016\/j.metabol.2020.154433 (2021).","journal-title":"Metabolism"},{"issue":"1","key":"26752_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.metabol.2020.154433","volume":"71","author":"A Mantovani","year":"2021","unstructured":"Mantovani, A. et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: An updated meta-analysis. Gut 71(1), 156\u2013162. https:\/\/doi.org\/10.1016\/j.metabol.2020.154433 (2021).","journal-title":"Gut"},{"issue":"7","key":"26752_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001680","volume":"11","author":"G Musso","year":"2014","unstructured":"Musso, G. et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis. PLoS Med. 11(7), e1001680. https:\/\/doi.org\/10.1371\/journal.pmed.1001680 (2014).","journal-title":"PLoS Med."},{"key":"26752_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","volume":"79","author":"A Mantovani","year":"2018","unstructured":"Mantovani, A. et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism 79, 64\u201376. https:\/\/doi.org\/10.1016\/j.metabol.2017.11.003 (2018).","journal-title":"Metabolism"},{"issue":"3","key":"26752_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"A Berzigotti","year":"2021","unstructured":"Berzigotti, A. et al. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis: 2021 update. J Hepatol. 75(3), 659\u2013689. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025 (2021).","journal-title":"J Hepatol."},{"issue":"8","key":"26752_CR17","doi-asserted-by":"publisher","first-page":"102814","DOI":"10.1016\/j.dsx.2023.102814","volume":"17","author":"R Supriyadi","year":"2023","unstructured":"Supriyadi, R., Yanto, T. A., Hariyanto, T. I. & Suastika, K. Utility of non-invasive liver fibrosis markers to predict the incidence of chronic kidney disease (CKD): A systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 17(8), 102814. https:\/\/doi.org\/10.1016\/j.dsx.2023.102814 (2023).","journal-title":"Diabetes Metab Syndr."},{"key":"26752_CR18","doi-asserted-by":"publisher","unstructured":"Ciardullo S, Ballabeni C, Trevisan R, Perseghin G (2022) Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis. Biomolecules. https:\/\/doi.org\/10.3390\/biom12010105.","DOI":"10.3390\/biom12010105"},{"issue":"2","key":"26752_CR19","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","volume":"80","author":"V Ratziu","year":"2024","unstructured":"Ratziu, V. & Boursier, J. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol. 80(2), e51\u2013e52. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.017 (2024).","journal-title":"J Hepatol."},{"issue":"1","key":"26752_CR20","doi-asserted-by":"publisher","first-page":"11753","DOI":"10.1038\/s41598-021-88285-6","volume":"11","author":"H Saito","year":"2021","unstructured":"Saito, H. et al. High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes. Sci Rep. 11(1), 11753. https:\/\/doi.org\/10.1038\/s41598-021-88285-6 (2021).","journal-title":"Sci Rep."},{"key":"26752_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/2040622321104864","author":"Y Cao","year":"2021","unstructured":"Cao, Y. et al. The association between NAFLD and risk of chronic kidney disease: A cross-sectional study. Ther Adv Chronic Dis https:\/\/doi.org\/10.1177\/2040622321104864 (2021).","journal-title":"Ther Adv Chronic Dis"},{"key":"26752_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000904","author":"S Ciardullo","year":"2020","unstructured":"Ciardullo, S. et al. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diabetes Res Care. https:\/\/doi.org\/10.1136\/bmjdrc-2019-000904 (2020).","journal-title":"BMJ Open Diabetes Res Care."},{"issue":"33","key":"26752_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021038","volume":"99","author":"E Han","year":"2020","unstructured":"Han, E. et al. Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes. Medicine (Baltimore) 99(33), e21038. https:\/\/doi.org\/10.1097\/MD.0000000000021038 (2020).","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"26752_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101497","volume":"50","author":"A Mantovani","year":"2024","unstructured":"Mantovani, A. et al. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus. Diabetes Metab. 50(1), 101497. https:\/\/doi.org\/10.1016\/j.diabet.2023.101497 (2024).","journal-title":"Diabetes Metab."},{"issue":"12","key":"26752_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279367","volume":"17","author":"EH Nah","year":"2022","unstructured":"Nah, E. H. et al. Chronic kidney disease in nonalcoholic fatty liver disease at primary healthcare centers in Korea. PLoS ONE 17(12), e0279367. https:\/\/doi.org\/10.1371\/journal.pone.0279367 (2022).","journal-title":"PLoS ONE"},{"key":"26752_CR26","doi-asserted-by":"publisher","first-page":"630","DOI":"10.4093\/dmj.2021.0130","volume":"46","author":"DH Seo","year":"2022","unstructured":"Seo, D. H. & Kim, S. H. Advanced liver fibrosis is associated with chronic kidney disease in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Diabetes Metab J. 46, 630\u2013639. https:\/\/doi.org\/10.4093\/dmj.2021.0130 (2022).","journal-title":"Diabetes Metab J."},{"issue":"6","key":"26752_CR27","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jhep.2017.08.024","volume":"67","author":"DH Sinn","year":"2017","unstructured":"Sinn, D. H. et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. J Hepatol. 67(6), 1274\u20131280. https:\/\/doi.org\/10.1016\/j.jhep.2017.08.024 (2017).","journal-title":"J Hepatol."},{"issue":"9","key":"26752_CR28","doi-asserted-by":"publisher","first-page":"e3661","DOI":"10.1210\/clinem\/dgac382","volume":"107","author":"Y Sun","year":"2022","unstructured":"Sun, Y. et al. Fibrosis risk in nonalcoholic fatty liver disease is related to chronic kidney disease in older type 2 diabetes patients. J Clin Endocrinol Metab. 107(9), e3661\u2013e3669. https:\/\/doi.org\/10.1210\/clinem\/dgac382 (2022).","journal-title":"J Clin Endocrinol Metab."},{"key":"26752_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010171","author":"Y Seko","year":"2019","unstructured":"Seko, Y. et al. FIB-4 index and diabetes mellitus are associated with chronic kidney disease in japanese patients with non-alcoholic fatty liver disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21010171 (2019).","journal-title":"Int J Mol Sci."},{"issue":"3","key":"26752_CR30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/00365521.2019.1583366","volume":"54","author":"K \u00d6nnerhag","year":"2019","unstructured":"\u00d6nnerhag, K., Hartman, H., Nilsson, P. M. & Lindgren, S. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). Scand J Gastroenterol. 54(3), 328\u2013334. https:\/\/doi.org\/10.1080\/00365521.2019.1583366 (2019).","journal-title":"Scand J Gastroenterol."},{"issue":"4","key":"26752_CR31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/MEG.0000000000001045","volume":"30","author":"K Wijarnpreecha","year":"2018","unstructured":"Wijarnpreecha, K., Thongprayoon, C., Scribani, M., Ungprasert, P. & Cheungpasitporn, W. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA. Eur J Gastroenterol Hepatol. 30(4), 404\u2013410. https:\/\/doi.org\/10.1097\/MEG.0000000000001045 (2018).","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"26752_CR32","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2147\/DMSO.S292926","volume":"14","author":"Y Deng","year":"2021","unstructured":"Deng, Y., Zhao, Q. & Gong, R. Association between metabolic associated fatty liver disease and chronic kidney disease: A cross-sectional study from NHANES 2017\u20132018. Diabetes Metab Syndr Obes. 14, 1751\u20131761. https:\/\/doi.org\/10.2147\/DMSO.S292926 (2021).","journal-title":"Diabetes Metab Syndr Obes."},{"issue":"3","key":"26752_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jdiacomp.2017.12.010","volume":"32","author":"KH Williams","year":"2018","unstructured":"Williams, K. H., Burns, K. & Twigg, S. M. Differing clinical phenotype for higher alanine-aminotransferase (ALT) compared with high-risk NAFLD fibrosis score in type 2 diabetes mellitus. J Diabetes Complic. 32(3), 321\u2013324. https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.12.010 (2018).","journal-title":"J Diabetes Complic."},{"issue":"11","key":"26752_CR34","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.cgh.2023.02.024","volume":"21","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal, A. J. et al. Validation of a clinical risk-based classification system in a large nonalcoholic fatty liver disease real-world cohort. Clin Gastroenterol Hepatol. 21(11), 2889\u20132900 (2023).","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"26752_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12916-023-02891-x","volume":"21","author":"TJ Hydes","year":"2023","unstructured":"Hydes, T. J. et al. The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: A prospective cohort study using the UK Biobank. BMC Med. 21(1), 185. https:\/\/doi.org\/10.1186\/s12916-023-02891-x (2023).","journal-title":"BMC Med."},{"issue":"3","key":"26752_CR36","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s12072-023-10486-0","volume":"17","author":"S Chen","year":"2023","unstructured":"Chen, S., Pang, J., Huang, R., Xue, H. & Chen, X. Association of MAFLD with end-stage kidney disease: A prospective study of 337,783 UK Biobank participants. Hepatol Int. 17(3), 595\u2013605. https:\/\/doi.org\/10.1007\/s12072-023-10486-0 (2023).","journal-title":"Hepatol Int."},{"issue":"4","key":"26752_CR37","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s10620-021-06955-x","volume":"67","author":"N Noureddin","year":"2022","unstructured":"Noureddin, N., Noureddin, M., Singh, A. & Alkhouri, N. Progression of nonalcoholic fatty liver disease-associated fibrosis in a large cohort of patients with type 2 diabetes. Dig Dis Sci. 67(4), 1379\u20131388. https:\/\/doi.org\/10.1007\/s10620-021-06955-x (2022).","journal-title":"Dig Dis Sci."},{"issue":"1 Pt 3","key":"26752_CR38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jfma.2019.07.007","volume":"119","author":"MH Hsieh","year":"2020","unstructured":"Hsieh, M. H. et al. Higher NAFLD fibrosis score is associated with impaired eGFR. J Formos Med Assoc. 119(1 Pt 3), 496\u2013503. https:\/\/doi.org\/10.1016\/j.jfma.2019.07.007 (2020).","journal-title":"J Formos Med Assoc."},{"issue":"2","key":"26752_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088569","volume":"9","author":"G Sesti","year":"2014","unstructured":"Sesti, G. et al. Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease. PLoS ONE 9(2), e88569. https:\/\/doi.org\/10.1371\/journal.pone.0088569 (2014).","journal-title":"PLoS ONE"},{"issue":"10","key":"26752_CR40","doi-asserted-by":"publisher","first-page":"e3957","DOI":"10.1210\/clinem\/dgab425","volume":"106","author":"G Zuo","year":"2021","unstructured":"Zuo, G. et al. New nonalcoholic fatty liver disease and fibrosis progression associate with the risk of incident chronic kidney disease. J Clin Endocrinol Metab. 106(10), e3957\u2013e3968. https:\/\/doi.org\/10.1210\/clinem\/dgab425 (2021).","journal-title":"J Clin Endocrinol Metab."},{"issue":"1 Pt 1","key":"26752_CR41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jfma.2019.02.010","volume":"119","author":"PC Chen","year":"2020","unstructured":"Chen, P. C. et al. The correlation between fatty liver disease and chronic kidney disease. J Formos Med Assoc. 119(1 Pt 1), 42\u201350. https:\/\/doi.org\/10.1016\/j.jfma.2019.02.010 (2020).","journal-title":"J Formos Med Assoc."},{"issue":"1","key":"26752_CR42","doi-asserted-by":"publisher","first-page":"12645","DOI":"10.1038\/s41598-024-63386-0","volume":"14","author":"C Cen","year":"2024","unstructured":"Cen, C., Fan, Z., Ding, X., Tu, X. & Liu, Y. Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: A national retrospective cohort study. Sci Rep. 14(1), 12645 (2024).","journal-title":"Sci Rep."},{"issue":"1","key":"26752_CR43","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1080\/0886022X.2022.2144373","volume":"44","author":"Q Hu","year":"2022","unstructured":"Hu, Q., Chen, Y., Bao, T. & Huang, Y. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: A Chinese population-based study. Ren Fail. 44(1), 1996\u20132005. https:\/\/doi.org\/10.1080\/0886022X.2022.2144373 (2022).","journal-title":"Ren Fail."},{"issue":"1","key":"26752_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jceh.2017.12.005","volume":"9","author":"RV Nampoothiri","year":"2019","unstructured":"Nampoothiri, R. V. et al. Renal dysfunction in patients with nonalcoholic fatty liver disease is related to the presence of diabetes mellitus and severity of liver Disease. J Clin Exp Hepatol. 9(1), 22\u201328. https:\/\/doi.org\/10.1016\/j.jceh.2017.12.005 (2019).","journal-title":"J Clin Exp Hepatol."},{"issue":"3","key":"26752_CR45","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00125-021-05627-9","volume":"65","author":"CY Jung","year":"2022","unstructured":"Jung, C. Y. et al. Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. Diabetologia 65(3), 518\u2013527. https:\/\/doi.org\/10.1007\/s00125-021-05627-9 (2022).","journal-title":"Diabetologia"},{"key":"26752_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108884","volume":"177","author":"I Mikolasevic","year":"2021","unstructured":"Mikolasevic, I. et al. Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study. Diabetes Res Clin Pract. 177, 108884. https:\/\/doi.org\/10.1016\/j.diabres.2021.108884 (2021).","journal-title":"Diabetes Res Clin Pract."},{"issue":"4","key":"26752_CR47","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.diabet.2019.11.004","volume":"46","author":"A Mantovani","year":"2020","unstructured":"Mantovani, A. et al. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab. 46(4), 296\u2013303. https:\/\/doi.org\/10.1016\/j.diabet.2019.11.004 (2020).","journal-title":"Diabetes Metab."},{"key":"26752_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.09.020","author":"MW Yeung","year":"2017","unstructured":"Yeung, M. W. et al. Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2017.09.020 (2017).","journal-title":"J Hepatol."},{"issue":"2","key":"26752_CR49","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/liv.14274","volume":"40","author":"R Lombardi","year":"2020","unstructured":"Lombardi, R. et al. Liver fibrosis by FibroScan(\u00ae) independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. Liver Int. 40(2), 347\u2013354. https:\/\/doi.org\/10.1111\/liv.14274 (2020).","journal-title":"Liver Int."},{"issue":"6","key":"26752_CR50","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/MEG.0000000000002767","volume":"36","author":"W Zhang","year":"2024","unstructured":"Zhang, W. et al. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease. Eur J Gastroenterol Hepatol. 36(6), 802\u2013810. https:\/\/doi.org\/10.1097\/MEG.0000000000002767 (2024).","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"1","key":"26752_CR51","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/HEP.0000000000000845","volume":"81","author":"RK Sterling","year":"2025","unstructured":"Sterling, R. K. et al. AASLD practice guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology 81(1), 321\u2013357. https:\/\/doi.org\/10.1097\/HEP.0000000000000845 (2025).","journal-title":"Hepatology"},{"issue":"17","key":"26752_CR52","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.3748\/wjg.v27.i17.1864","volume":"27","author":"R Heda","year":"2021","unstructured":"Heda, R. et al. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol. 27(17), 1864\u20131882. https:\/\/doi.org\/10.3748\/wjg.v27.i17.1864 (2021).","journal-title":"World J Gastroenterol."},{"issue":"39","key":"26752_CR53","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.3748\/wjg.v28.i39.5691","volume":"28","author":"P Theofilis","year":"2022","unstructured":"Theofilis, P., Vordoni, A. & Kalaitzidis, R. G. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol. 28(39), 5691\u20135706. https:\/\/doi.org\/10.3748\/wjg.v28.i39.5691 (2022).","journal-title":"World J Gastroenterol."},{"issue":"2","key":"26752_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100067","volume":"2","author":"K Patel","year":"2020","unstructured":"Patel, K. & Sebastiani, G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2(2), 100067. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100067 (2020).","journal-title":"JHEP Rep."},{"issue":"39","key":"26752_CR55","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.3748\/wjg.v30.i39.4324","volume":"30","author":"A Singh","year":"2024","unstructured":"Singh, A., Sohal, A. & Batta, A. Recent developments in non-invasive methods for assessing metabolic dysfunction-associated fatty liver disease. World J Gastroenterol. 30(39), 4324\u20134328. https:\/\/doi.org\/10.3748\/wjg.v30.i39.4324 (2024).","journal-title":"World J Gastroenterol."},{"key":"26752_CR56","doi-asserted-by":"publisher","unstructured":"Qin, S.,  Wang, S., Wang, X., Wang, J. Liver stiffness assessed by transient elastography as a potential indicator of chronic kidney disease in patients with nonalcoholic fatty liver disease J. Clin. Lab. Anal. 33(2) https:\/\/doi.org\/10.1002\/jcla.2019.33.issue-210.1002\/jcla.22657 (2019).","DOI":"10.1002\/jcla.2019.33.issue-210.1002\/jcla.22657"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26752-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26752-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26752-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:24:18Z","timestamp":1764325458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26752-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26752"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26752-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42681"}}